BioInvent International AB (BINV) - Total Assets
Based on the latest financial reports, BioInvent International AB (BINV) holds total assets worth Skr916.67 Million SEK (≈ $98.65 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BioInvent International AB - Total Assets Trend (2000–2024)
This chart illustrates how BioInvent International AB's total assets have evolved over time, based on quarterly financial data. Also see BINV market cap for the company's overall valuation and market capitalisation.
BioInvent International AB - Asset Composition Analysis
Current Asset Composition (December 2024)
BioInvent International AB's total assets of Skr916.67 Million consist of 95.4% current assets and 4.7% non-current assets. Review BINV liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 44.0% |
| Accounts Receivable | Skr31.25 Million | 3.2% |
| Inventory | Skr10.97 Million | 1.1% |
| Property, Plant & Equipment | Skr46.02 Million | 4.7% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2000–2024)
This chart illustrates how BioInvent International AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See BINV stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BioInvent International AB's current assets represent 95.4% of total assets in 2024, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 44.0% of total assets in 2024, down from 72.7% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2000.
- Asset Diversification: The largest asset category is property, plant & equipment at 4.7% of total assets.
BioInvent International AB Competitors by Total Assets
Key competitors of BioInvent International AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
BioInvent International AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.59 | 12.30 | 15.11 |
| Quick Ratio | 8.49 | 12.18 | 15.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr774.60 Million | Skr1.03 Billion | Skr629.73 Million |
BioInvent International AB - Advanced Valuation Insights
This section examines the relationship between BioInvent International AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.27 |
| Latest Market Cap to Assets Ratio | 0.16 |
| Asset Growth Rate (YoY) | -29.3% |
| Total Assets | Skr989.24 Million |
| Market Capitalization | $160.04 Million USD |
Valuation Analysis
Below Book Valuation: The market values BioInvent International AB's assets below their book value (0.16x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: BioInvent International AB's assets decreased by 29.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for BioInvent International AB (2000–2024)
The table below shows the annual total assets of BioInvent International AB from 2000 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr989.24 Million ≈ $106.46 Million |
-29.35% |
| 2023-12-31 | Skr1.40 Billion ≈ $150.68 Million |
-18.22% |
| 2022-12-31 | Skr1.71 Billion ≈ $184.26 Million |
+18.30% |
| 2021-12-31 | Skr1.45 Billion ≈ $155.75 Million |
+80.32% |
| 2020-12-31 | Skr802.64 Million ≈ $86.38 Million |
+254.98% |
| 2019-12-31 | Skr226.11 Million ≈ $24.33 Million |
+87.80% |
| 2018-12-31 | Skr120.40 Million ≈ $12.96 Million |
-29.20% |
| 2017-12-31 | Skr170.05 Million ≈ $18.30 Million |
-38.46% |
| 2016-12-31 | Skr276.30 Million ≈ $29.73 Million |
+407.46% |
| 2015-12-31 | Skr54.45 Million ≈ $5.86 Million |
-26.53% |
| 2014-12-31 | Skr74.11 Million ≈ $7.98 Million |
-9.00% |
| 2013-12-31 | Skr81.44 Million ≈ $8.76 Million |
-30.12% |
| 2012-12-31 | Skr116.54 Million ≈ $12.54 Million |
-43.36% |
| 2011-12-31 | Skr205.76 Million ≈ $22.14 Million |
+49.07% |
| 2010-12-31 | Skr138.03 Million ≈ $14.85 Million |
+9.33% |
| 2009-12-31 | Skr126.25 Million ≈ $13.59 Million |
-57.27% |
| 2008-12-31 | Skr295.43 Million ≈ $31.79 Million |
+9.01% |
| 2007-12-31 | Skr271.00 Million ≈ $29.16 Million |
+82.70% |
| 2006-12-31 | Skr148.33 Million ≈ $15.96 Million |
-44.31% |
| 2005-12-31 | Skr266.34 Million ≈ $28.66 Million |
+11.72% |
| 2004-12-31 | Skr238.41 Million ≈ $25.66 Million |
-30.53% |
| 2003-12-31 | Skr343.19 Million ≈ $36.93 Million |
-23.12% |
| 2002-12-31 | Skr446.41 Million ≈ $48.04 Million |
+8.73% |
| 2001-12-31 | Skr410.55 Million ≈ $44.18 Million |
+111.34% |
| 2000-12-31 | Skr194.26 Million ≈ $20.91 Million |
-- |
About BioInvent International AB
BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company's drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and a type of blood cancer; BI-1206, an a… Read more